

# Methodological Note

---

ADVANZ PHARMA is committed to ensuring transparency of relationships with patients and patient organisations (POs) by operating within the Association of British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry in alignment with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on Disclosure on Transfers of Value.

Transfers of Value (ToV) i.e. payments or benefits received by patients and POs during the 2021 calendar year will be disclosed on a ADVANZ PHARMA external facing website, <https://www.advanzpharma.com/>

The principles applied in this methodological note are relevant to the UK which follow the EFPIA Code of practice.

## Definitions

### Individuals representing Patient Organisations

'Individuals representing patient organisations' means a person who is mandated to represent and express the views of a patient organisation.

### Patient Organisations (POs)

'Patient organisation' means an organization mainly comprising of patients and/or caregivers or any user organisation such as a disability organisation, carer or relative organisation and consumer organisation that represents and/or supports the needs of patients and/or caregivers.

## Disclosure Categories

In 2021 ADVANZ PHARMA has disclosed the following financial payments:

1. Transfers of value to patient organisations (POs)
  - i. For payments made to patient organisations or institutions in relation to meetings. This includes fees for service paid to patient organisations or any type of funding by companies not otherwise covered by the relevant codes.

## ToV Transaction Principles

### VAT

For all ToVs VAT is excluded.

### **Transaction Date**

ADVANZ PHARMA will disclose a transfer of value when internal approval for a project/activity is given and the money is allocated. This may mean that some projects approved in 2021 will be disclosed as part of the 2021 annual reporting period even though the payment may not occur until 2021.

### **Multi-Year Projects**

Where projects run for several years ADVANZ PHARMA will declare the amount paid relevant to the year in which each part of the payment was made. Thus a project which spans 4 calendar years and includes several individual transfers of value during that time will have four associated disclosures; one for each calendar year showing the value of the transfer made in that specific calendar year.

### **Cross-Border Payments**

All disclosures are made in the country in which the patients or PO practice is located. Payments made to UK-based patients or organisations by ADVANZ PHARMA overseas operations are disclosed within the UK.

### **Co-Marketing Projects**

Where ADVANZ PHARMA jointly markets a product with another pharmaceutical company, ADVANZ PHARMA will only declare those payments made directly from ADVANZ PHARMA bank accounts and listed in the company records as part of its normal business operations. Transfers of value made by its co-marketing partners will be disclosed separately by those organisations.

## **Patient Payments**

### **Data Privacy**

In accordance with Data Privacy law, ADVANZ PHARMA has obtained and retained records of consent from patients on an individual activity basis prior to disclosing personal data such as individual transfers of value. Where permission has not been obtained or where patients have refused consent, ADVANZ PHARMA has declared the total spend as an aggregate figure given on a separate line entry within the relevant disclosure category and the % of non-consenting patients given as a percentage of the total patients receiving a ToV.

### **Fee Payments to Charities**

Patients who have worked with ADVANZ PHARMA may ask for their fee to be paid to charity. ADVANZ PHARMA does not encourage this type of fee payment and all payments are normally made directly to the patient; where payment to a charity may occur the disclosure is still made against the individual patient.

## **Medical Education Grants**

ADVANZ PHARMA has been occasionally approached by independent companies to provide funding in relation to medical education projects. ADVANZ PHARMA's funding policies in these circumstances

require that ADVANZ PHARMA has no influence over the details of the project. As ADVANZ PHARMA would not influence or select participants involved in such projects, ADVANZ PHARMA would disclose such payments under an PO category where such definition is met by the independent company.

### **Contributions to Meetings**

ADVANZ PHARMA will disclose all payments made to medical associations, patient organisations, institutions in relation to meetings. This includes direct funding such as sponsorship fees, and indirect support such as providing a logistics agency or subsidising the cost of registration fees.

All costs associated with meetings run solely by ADVANZ PHARMA are outside the scope of disclosure except for fees paid to individual patients or patient organisations providing services as speakers.

### **Patient Organisations**

All transfers of value to UK-based patient organisations are disclosed directly on ADVANZ PHARMA's Website (<https://www.advanzpharma.com/ethics-transparency>).

### **OTC and Medical Devices**

There are no disclosures related to OTC medicines and Medical Devices.